Last night, OPM released its FY24 update, most notably revealing 1/ a EUR 5.1m cash position forcing prioritization of research programs + implementation of a cost-cutting plan, and 2/ the intention to secure new partnerships to advance OPM-101 for IBD and OPM-201 for Parkinson's (PD). Recently, the company also announced its intention to conduct a Ph1b/2a trial with OPM-101 + pembrolizumab for advanced anti-PD1 resistant melanoma. Remember that OPM-101 previously displayed encouraging antitumor ....
